TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16402597

Group type: EXPERIMENTAL
Intervention: Point process adaptive filter algorithm applied to simulated heartbeat data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point process adaptive filter algorithm applied to actual heartbeat data from a tilt table experiment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point process adaptive filter algorithm applied to actual heartbeat data from healthy subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point process adaptive filter algorithm applied to actual heartbeat data from subjects with congestive heart failure
Number of subjects: 0
Study: 15021280

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous bolus of dexamethasone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study: 11266371

Group type: EXPERIMENTAL
Intervention: Wheat bran fiber (WBF) intervention
Number of subjects: 1287
Study: 9650498

Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 61
Study: 8504633

Group type: EXPERIMENTAL
Intervention: Blood flow to forearm and calf muscles
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Forearm blood flow
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Calf blood flow
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Blood flow to forearm skin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Blood flow to forearm adipose tissue
Number of subjects: 5
Study: 3440615

Group type: EXPERIMENTAL
Intervention: Aspiration of the elbow and instillation of local anaesthetic
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Early active movement encouraged
Number of subjects: 80

Group type: COMPARATOR
Intervention: Retrospective controls (delayed active movement)
Number of subjects: 80
Study: 29409469

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard oesophagectomy
Number of subjects: 300
Study: 27210780

Group type: EXPERIMENTAL
Intervention: Gastro-Laryngeal Tube (GLT)
Number of subjects: 80
Study: 26508448

Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty
Number of subjects: 39

Group type: COMPARATOR
Intervention: High-pressure balloon angioplasty
Number of subjects: 39
Study: 23687222

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir for 7 or 21 days
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir for 7 or 21 days
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine for 7 or 21 days
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: CYP2B6 983T → C genotype
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: CYP2B6 516G → T genotype
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Emergent resistance
Number of subjects: 301
Study: 20502415

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 188

Group type: COMPARATOR
Intervention: High-dose CCB (group C)
Number of subjects: 188

Group type: COMPARATOR
Intervention: High-dose ARB (group D)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Low-dose combination therapy (CCB plus ARB, group E)
Number of subjects: 188
Study: 18426826

Group type: EXPERIMENTAL
Intervention: I131 treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no I131 treatment)
Number of subjects: 40
Study: 16796484

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Number of subjects: 236

Group type: COMPARATOR
Intervention: Minimum Intervention
Number of subjects: 236
Study: 12865039

Group type: EXPERIMENTAL
Intervention: Nondihydropyridine CCB (verapamil SR 240 mg/day)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (trandolapril 2 mg/day)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Combination of verapamil SR (180 mg/day) plus trandolapril (2 mg/day)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/day)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Verapamil SR (180 mg/day) plus trandolapril (2 mg/day)
Number of subjects: 1209
Study: 10402686

Group type: EXPERIMENTAL
Intervention: OCD group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anxious controls
Number of subjects: 40

Group type: COMPARATOR
Intervention: Undergraduate students
Number of subjects: 40
Study: 7487856

Group type: EXPERIMENTAL
Intervention: One session therapist‐directed exposure (maximum 3 hours)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Specific manual‐based treatment at the clinic
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Specific manual‐based treatment in the home
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: General manual‐based treatment in the home
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: General manual‐based treatment at the clinic
Number of subjects: 52
Study: 2303015

Group type: EXPERIMENTAL
Intervention: Sepulveda Epilepsy Education program (SEE)
Number of subjects: 38
Study: 6996620

Group type: EXPERIMENTAL
Intervention: FPL 52758 (10 microgram, i.d. injection)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FPL 52758 (1.5 mg, topical application under occlusion for 24 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: FPL 57787 (5% ointment)
Number of subjects: 20
Study: 29580592

Group type: EXPERIMENTAL
Intervention: Palpation method for ETTc inflation
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Minimum occlusive volume technique for ETTc inflation
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Minimum leak technique for ETTc inflation
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Air-return back into the syringe method for ETTc inflation
Number of subjects: 139
Study: 27894306

Group type: EXPERIMENTAL
Intervention: Killed whole-HIV vaccine, SAV001
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Killed whole-HIV vaccine, SAV001 with adjuvant
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 25171042

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: DFDBA with saline
Number of subjects: 24
Study: 24474097

Group type: EXPERIMENTAL
Intervention: Lactic acid (85%) + sunscreen
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Glycolic acid (70%) + sunscreen
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (sunscreen only)
Number of subjects: 27
Study: 19875684

Group type: EXPERIMENTAL
Intervention: 20 mg sildenafil
Number of subjects: 20
Study: 19133945

Group type: EXPERIMENTAL
Intervention: Intensive, preventive‐based, non‐invasive management of dental caries
Number of subjects: 902

Group type: COMPARATOR
Intervention: Control group (standard management of dental caries)
Number of subjects: 902
Study: 16418408

Group type: EXPERIMENTAL
Intervention: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days)
Number of subjects: 156

Group type: COMPARATOR
Intervention: 10-day sequential regimen
Number of subjects: 156
Study: 12831223

Group type: EXPERIMENTAL
Intervention: Glass polyphosphonate cement (Diamond)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Glass polyalkenoate cement (Ketac‐Cem)
Number of subjects: 31
Study: 10594394

Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg/week
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg/week
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methotrexate dose escalation from 15 to 25 mg/week
Number of subjects: 32
Study: 8686833

Group type: EXPERIMENTAL
Intervention: pethidine 25 mg (1 ml)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: lignocaine 10 mg (1 ml)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.9% saline (1 ml)
Number of subjects: 150
Study: 1776542

Group type: EXPERIMENTAL
Intervention: Behavior therapy plus cognitive therapy (BT + CT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Behavior therapy plus nutrition education (BT + NE)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Behavior therapy plus cognitive therapy and nutrition education (BT + CT + NE)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Behavior therapy plus social support (BT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cognitive groups
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 69
Study: 7315774

Group type: EXPERIMENTAL
Intervention: Beef diet (one egg and at least 5 oz of beef daily for 3 months)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Poultry and fish diet (one egg and at least 5 oz of poultry and fish daily for 3 months)
Number of subjects: 129
Study: 3882217

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (doxorubicin ≤ 550 mg/m2, cyclophosphamide ≤ 5500 mg/m2, methotrexate ≤ 1000 mg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 31
Study: 31067122

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP) adherence measured by intracellular tenofovir-diphosphate (TFV-DP) levels
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Partnership type (no/single, single+, multi)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: mCalcR Score (risk assessment)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Partnership type change
Number of subjects: 313
Study: 29633367

Group type: EXPERIMENTAL
Intervention: CL + PDT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FL + PDT
Number of subjects: 15
Study: 27897610

Group type: EXPERIMENTAL
Intervention: Calcitriol (1,000 IU daily for 6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23989533

Group type: EXPERIMENTAL
Intervention: Tecadenoson (75, 150, or 300 μg intravenous)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Esmolol (100 μg/kg/min for 10 min then 50 μg/kg/min for 50 min)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of Tecadenoson and Esmolol
Number of subjects: 21
Study: 23025048

Group type: EXPERIMENTAL
Intervention: Emoxipin (single dose, 150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexidol (single dose, 300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reamberin (single dose, 400 ml 1.5% solution)
Number of subjects: 0
Study: 20306537

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 200
Study: 18634953

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 24
Study: 15678536

Group type: EXPERIMENTAL
Intervention: Spin-echo EPI at 3 T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low threshold to identify activated voxels
Number of subjects: 0
Study: 11802037

Group type: EXPERIMENTAL
Intervention: Intranasal azelastine (two puffs twice a day, 548 microg/d for 2 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intranasal azelastine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10391281

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Off-pump surgery with arterial and vein grafts
Number of subjects: 32

Group type: COMPARATOR
Intervention: CPB group
Number of subjects: 32
Study: 8631089

Group type: EXPERIMENTAL
Intervention: 20 micrograms recombinant DNA vaccinia vaccines against hepatitis B; administered at newborn, 1 month, and 6 months.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 20 micrograms genetic engineering vaccines against hepatitis B; administered at same intervals as group 1.
Number of subjects: 142

Group type: COMPARATOR
Intervention: 10 micrograms genetic engineering vaccines against hepatitis B plus HBIG (1ml, 200 U/ml); administered at same intervals as group 1.
Number of subjects: 142
Study: 2178852

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (behavioral smoking-cessation program without nicotine patch)
Number of subjects: 65
Study: 6104934

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 118
Study: 30663425

Group type: EXPERIMENTAL
Intervention: CRet trial
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham trial
Number of subjects: 16
Study: 30372779

Group type: EXPERIMENTAL
Intervention: HPA lanolin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 180
Study: 27022913

Group type: EXPERIMENTAL
Intervention: Structured Low Fat (SLF, 55% carbohydrate; 20% protein; 25% fat, n = 36)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Structured Modified Carbohydrate (SMC, 35% carbohydrate; 30% protein; 35% fat, n = 37)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Wait listed control group (n = 14)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Structured Low Fat (SLF)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Structured Modified Carbohydrate (SMC)
Number of subjects: 87
Study: 24521874

Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg/day over four weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 22344231

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFN-α
Number of subjects: 0
Study: 19450036

Group type: EXPERIMENTAL
Intervention: Genetic risk information for diabetes, heart disease, colon cancer, or lung cancer with lifetime risk varying by 10% increments (20% to 100%).
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Genetic risk information for diabetes, heart disease, colon cancer, or lung cancer.
Number of subjects: 752
Study: 17454718

Group type: EXPERIMENTAL
Intervention: Pictures containing smoking related‐content
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pictures devoid of smoking content
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fixation cross
Number of subjects: 23
Study: 15174545

Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction
Number of subjects: 108

Group type: COMPARATOR
Intervention: Single-bundle reconstruction
Number of subjects: 108
Study: 10601673

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine (75, 150, or 300 micrograms)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (150, 300, or 600 micrograms)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural clonidine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intrathecal and epidural clonidine
Number of subjects: 24
Study: 9351353

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 5
Study: 8382534

Group type: EXPERIMENTAL
Intervention: Nefazodone 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nefazodone 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nefazodone (all doses)
Number of subjects: 8
Study: 3530224

Group type: EXPERIMENTAL
Intervention: Ceftazidime (cephalosporin) for 5 days at the operation
Number of subjects: 26

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 26
Study: 31634512

Group type: EXPERIMENTAL
Intervention: $10 incentive
Number of subjects: 3723

Group type: EXPERIMENTAL
Intervention: $20 incentive
Number of subjects: 3723

Group type: EXPERIMENTAL
Intervention: Proactive call
Number of subjects: 3723

Group type: COMPARATOR
Intervention: $10 incentive, no call
Number of subjects: 3723

Group type: COMPARATOR
Intervention: No incentive, no call
Number of subjects: 3723
Study: 28993389

Group type: EXPERIMENTAL
Intervention: ITEC-CHF (Innovative Telemonitoring Enhanced Care Programme)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care CHF
Number of subjects: 300
Study: 26233481

Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 μg
Number of subjects: 3394
Study: 23980081

Group type: EXPERIMENTAL
Intervention: Ibandronate 50 mg per day orally for 2 years
Number of subjects: 3023

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3023
Study: 21527567

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 29
Study: 18815937

Group type: EXPERIMENTAL
Intervention: Telemedical home blood pressure monitoring (T)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional monitoring of office blood pressure (C)
Number of subjects: 223
Study: 16430377

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 0.625 mg/kg/dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 1.25 mg/kg/dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 2.5 mg/kg/dose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12971850

Group type: EXPERIMENTAL
Intervention: rt‐PA at 0.9 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rt‐PA at 0.7 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no thrombolytic therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic groups vs Control group
Number of subjects: 0
Study: 10671904

Group type: EXPERIMENTAL
Intervention: sibutramine 20 mg + 0.5 g kg‐1 alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: sibutramine 20 mg + placebo alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo capsules + 0.5 g kg‐1 alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo capsules + placebo alcohol
Number of subjects: 20
Study: 9347598

Group type: EXPERIMENTAL
Intervention: Gabapentin (2400 mg over 48 h)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8407006

Group type: EXPERIMENTAL
Intervention: Intracoronary nifedipine (0.2 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 3536231

Group type: EXPERIMENTAL
Intervention: Oral prednisolone/prednisone for four months
Number of subjects: 34

Group type: COMPARATOR
Intervention: No corticosteroid therapy (Control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 34
Study: 30953107

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg s.c.
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 29237033

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29118231

Group type: EXPERIMENTAL
Intervention: Tailored strategies to engage referring sites and patients
Number of subjects: 223
Study: 25288048

Group type: EXPERIMENTAL
Intervention: Comprehensive physiotherapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Sham therapy (neck massage)
Number of subjects: 111

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 111
Study: 23664859

Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking with riboflavin photosensitization and ultraviolet irradiation
Number of subjects: 16
Study: 20362849

Group type: EXPERIMENTAL
Intervention: Trypan blue 0.1% staining
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no trypan blue)
Number of subjects: 30
Study: 18238840

Group type: EXPERIMENTAL
Intervention: Compressomyograph (CMG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Mechanomyograph (MMG)
Number of subjects: 16
Study: 16735449

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rosiglitazone with lipid infusion
Number of subjects: 16
Study: 12749425

Group type: EXPERIMENTAL
Intervention: Modified long protocol (standard agonist dose until pituitary down-regulation, then halved during stimulation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified flare protocol (high dose of GnRH agonist for first 4 days, then standard agonist dose)
Number of subjects: 60
Study: 11100893

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 153
Study: 8140941

Group type: EXPERIMENTAL
Intervention: Cyclic estrogen‐progestagen replacement treatment plus nandrolone decanoate (ND)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cyclic estrogen‐progestagen replacement treatment (control group)
Number of subjects: 33
Study: 2457657

Group type: EXPERIMENTAL
Intervention: Etoposide + cisplatin (EP)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin (VAB-6)
Number of subjects: 164
Study: 29537903

Group type: EXPERIMENTAL
Intervention: Perioperative gum chewing
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Myopenia
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (without myopenia)
Number of subjects: 78
Study: 27940186

Group type: EXPERIMENTAL
Intervention: Longitudinal navigation by a lay health worker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control care
Number of subjects: 0
Study: 29264989

Group type: EXPERIMENTAL
Intervention: Mid-term multimodal psychotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 200
Study: 24094907

Group type: EXPERIMENTAL
Intervention: EMOTIV Headset
Number of subjects: 10

Group type: COMPARATOR
Intervention: Six disc electrodes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Comparison of electrode types (disc, needle, large squared)
Number of subjects: 10
Study: 21418411

Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% NaOCl followed by 17% EDTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% CX
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% CX followed by 17% EDTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (without irrigant solution)
Number of subjects: 60